This website uses cookies to improve your experience. Learn more about cookies and how to manage them.

Clinical Pharmacology Skills Alliance (CPSA)

abpi_logo.png     BPS-logo-600-x-300-transparent-no-gap-to-edge.png    abpi_logo-139.jpg    HEE-139.jpg

Who are the Clinical Pharmacology Skills Alliance?

The Clinical Pharmacology Skills Alliance (CPSA) launched in December 2017 as a partnership between the Association of the British Pharmaceutical Industry (ABPI), the British Pharmacological Society (BPS), the Faculty of Pharmaceutical Medicine (FPM) and Health Education England (HEE). The CPSA is led by an Executive Board, which is co-chaired by Professor Sir Munir Pirmohamed (BPS) and Andrew Foxley (AstraZeneca on behalf of ABPI).

Invest in clinical pharmacology for healthier patients, better medicines and a more efficient NHS

Investing in UK clinical pharmacology will help enhance the UK’s capacity to deliver clinical research in partnership with the NHS, strengthen the UK as a development base for new therapeutics and support patient care through the safe and effective use of medicines.
 
The purpose of the CPSA is to develop and deliver a long-term, cross-sector action plan for UK clinical pharmacology to help deliver aims identified nationally through the Industrial Strategy and the NHS Long-Term Plan. Our strategic objectives are to raise visibility, support training, develop partnerships, and take responsibility for the stewardship of UK clinical pharmacology.

Strategic objectives and successes

  1. Visibility: We will raise awareness of clinical pharmacology and develop opportunities for people to experience it first-hand. Our successes:
    • Engaging potential clinical pharmacologists through careers resources, presence at careers events, clinical pharmacology case studies and through Clinical Pharmacology Week, held annually in October.
    • Supporting opportunity through a mentoring scheme and by providing experience through foundation trainee taster weeks.
  2. Training: We will develop practical support to ensure clinical pharmacologists have a consistent, relevant and high-quality training experience. Our successes:
    • Developing a new Clinical Pharmacology Scientist apprenticeship. Apprentices will design, analyse, interpret and report clinical research and clinical trials in industry, CROs, academia and the NHS.
    • Reviewing and aligning curricula for medical training in both Clinical Pharmacology & Therapeutics and Pharmaceutical Medicine.
    • Producing a Specialty Trainee Training Charter, which is being piloted in London.
    • Working with the Specialty Advisory Committee and Training Programme Directors to run the first fully national training programme for clinical pharmacology trainees, including continuing to deliver BPS training and assessment annually.
    • Delivering clinical pharmacology themed training days for junior doctors to support training and improve recruitment to the specialty.
  3. Partnership:We will work in collaboration with the sector to determine where clinical pharmacology can add the most value, and develop partnerships with other professionals to increase our collective impact. Our successes:
    • Working with the Polypharmacy Service Consortium (a collaboration between Clinical Pharmacologists, Clinical Pharmacists, Geriatricians and General Practitioners) to support their vision that “for people on multiple medicines, every prescription should be personalised and should bring worthwhile benefit”.
    • Partnering with the Royal College of Physicians to deliver recommendations about implementing pharmacogenomics in the NHS.
  4. Stewardship: We will work with sector leaders to develop and implement a future-focused workforce strategy that meets the needs of the NHS and supports the UK life sciences industry. Our successes:
    • A joint Academy of Medical Sciences FORUM report exploring shared ambitions for UK clinical research and the steps that need to be taken to strengthen the clinical research workforce.
    • Joint CPSA policy consultation responses, covering topics which include NHS workforce strategy, NHS Long-Term Plan and the UK skills base
Read more about clinical pharmacology skills.

 
Professor Sir Munir Pirmohamed (CPSA co-chair, BPS):
 

Clinical pharmacologists have expertise across the whole research spectrum from early phase trials to applied research. They are experts in translational approaches to developing new drugs, improving the use of existing drugs, and contribute widely to the safe, effective and efficient use of medicines in the wider NHS – including health technology assessment and regulation. We need to invest in this specialty, and to ensure that clinical pharmacology expertise is accessible across the NHS.

Andrew Foxley (CPSA co-chair, AstraZeneca on behalf of ABPI):
 
Quote-begin.JPGClinical pharmacology clinicians and scientists are key contributors throughout the development of new medicines, and are responsible for designing and running the clinical trials that will be a key component in achieving a successful strategy for UK life sciences. The Clinical Pharmacology Skills Alliance brings together the right organisations with the expertise to support investment in these essential people across the broad spectrum of the skills pipeline. Quote-end.JPG
Professor Wendy Reid, Health Education England's Director of Education and Quality:
 
Quote-begin.JPGHealth Education England’s primary purpose is to ensure that the workforce of today and tomorrow has the right numbers, skills, values and behaviours, at the right time and in the right place. We recognise the important contribution that the Clinical Pharmacology workforce make to the NHS and the delivery of the Life Sciences agenda. We are delighted to be working in conjunction with our partners in the Clinical Pharmacology Alliance to support the development of the Clinical Pharmacology workforce. Quote-end.JPG
Professor Tim Higenbottam, President of the Faculty of Pharmaceutical Medicine RCP (UK):
 
Quote-begin.JPGClinical Pharmacology skills are critically important to the development of new medicines. The UK Life Sciences rely on training in the early medicines development, where safety is the first consideration. We have an enviable position for phase I trials, where the UK leads Europe but providing the pharmacology skills for scientists and doctors is an essential step to build global importance. The Alliance provides the voice that is needed to encourage education and awareness across the medical sciences. Quote-end.JPG